암 임상시험 상황 : 개발 동향 및 분석(2026년)

Cancer remains one of the leading causes of mortality worldwide, creating significant demand for innovative therapies across a broad range of tumor types. As pharmaceutical and biotechnology companies continue to expand their oncology pipelines, clinical trials have become a critical component of therapeutic development. The oncology segment accounts for one of the largest shares of global clinical research activity due to the complexity of cancer biology, the need for targeted therapies, and the continuous emergence of novel treatment modalities such as immunotherapies, cell therapies, gene therapies, antibody-drug conjugates, and precision oncology treatments.

The market has evolved significantly in recent years as advances in genomics, molecular diagnostics, and artificial intelligence have enabled more sophisticated trial designs. Sponsors are increasingly conducting biomarker-driven studies, adaptive trials, basket trials, umbrella trials, and decentralized clinical studies to accelerate drug development and improve success rates. As regulatory agencies continue to support innovative trial methodologies and expedited approval pathways, the oncology clinical trials market is expected to remain a major focus area for research investments and strategic partnerships.

Market Drivers

Rising Global Cancer Incidence

One of the primary factors driving market growth is the increasing incidence of cancer worldwide. Aging populations, lifestyle-related risk factors, environmental exposures, and improved disease detection are contributing to a growing number of cancer diagnoses.

The increasing patient population creates a strong demand for new treatment options, encouraging pharmaceutical and biotechnology companies to expand oncology research programs and initiate additional clinical trials.

Expansion of Precision Oncology

Precision medicine is transforming oncology drug development. The use of genomic profiling, molecular diagnostics, and biomarker testing enables researchers to identify patient subgroups that are more likely to respond to targeted therapies.

This shift toward personalized treatment approaches has increased the number of biomarker-driven clinical studies and created opportunities for more efficient trial designs with improved clinical outcomes.

Growing Oncology Drug Pipeline

The oncology sector continues to maintain one of the largest and most active drug development pipelines globally. Significant research activity is occurring across immunotherapies, targeted therapies, antibody-drug conjugates, cell therapies, radiopharmaceuticals, and gene-based treatments.

The growing number of investigational therapies entering clinical development is increasing demand for clinical trial services, patient recruitment solutions, data management platforms, and specialized research infrastructure.

Increased Research and Development Investments

Pharmaceutical companies, biotechnology firms, research institutions, and government organizations continue to increase investments in oncology research. Funding support for cancer treatment innovation is accelerating trial initiation and expanding the number of studies conducted across multiple cancer indications.

Growing collaboration among sponsors, contract research organizations, healthcare providers, and academic institutions is further strengthening market growth.

Market Restraints

High Clinical Trial Costs

Oncology trials are among the most expensive clinical studies due to complex protocols, extensive biomarker testing, long patient follow-up periods, advanced imaging requirements, and sophisticated data analysis needs.

The substantial financial burden associated with oncology research may limit participation by smaller organizations and increase overall development risks.

Patient Recruitment Challenges

Many oncology studies require highly specific patient populations defined by tumor type, disease stage, genetic mutations, or biomarker status. Recruiting eligible participants can be time-consuming and may delay trial completion.

Competition among multiple studies targeting similar patient populations further increases recruitment challenges.

Regulatory and Operational Complexity

Oncology trials must comply with stringent regulatory requirements related to patient safety, efficacy assessment, data integrity, and ethical standards. Global studies often require coordination across multiple countries, healthcare systems, and regulatory environments.

These complexities can increase operational costs and prolong development timelines.

Technology and Segment Insights

The global oncology clinical trials market can be segmented by phase type, study design, cancer indication, trial model, end user, and geography.

By phase type, the market includes Phase I, Phase II, Phase III, and Phase IV clinical trials. Phase III studies account for a significant share of market activity due to larger patient enrollment requirements, extensive global participation, and regulatory approval objectives. Early-stage Phase I studies are also expanding rapidly as companies evaluate novel therapeutic platforms and first-in-human treatments.

By study design, the market includes interventional studies, observational studies, adaptive trials, basket trials, umbrella trials, and expanded access studies. Interventional studies currently dominate the market due to their central role in regulatory submissions and therapeutic evaluation. However, observational studies are gaining importance as real-world evidence becomes increasingly valuable in oncology research.

By cancer indication, the market includes lung cancer, breast cancer, colorectal cancer, prostate cancer, gastric cancer, liver cancer, hematologic malignancies, skin cancer, ovarian cancer, pancreatic cancer, and other oncology indications. Lung cancer remains one of the largest segments due to extensive research activity involving targeted therapies and immunotherapies. Breast cancer trials are also expanding rapidly as developers pursue innovative treatment strategies and biomarker-based approaches.

By trial model, the market includes traditional site-based trials, decentralized clinical trials, hybrid clinical trials, and virtual trial approaches. Decentralized and hybrid models are gaining momentum as sponsors seek to improve patient participation, reduce operational burdens, and enhance data collection efficiency.

By end user, the market serves pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations (CROs), hospitals, and cancer research centers. Pharmaceutical and biotechnology companies account for the largest market share due to their substantial investment in oncology drug development.

Technological innovation continues to reshape the market through artificial intelligence-assisted patient recruitment, genomic sequencing, digital biomarkers, wearable monitoring devices, electronic health records integration, predictive analytics, and real-world evidence platforms. AI-based patient matching and molecular profiling technologies are improving enrollment efficiency and enabling more precise trial execution.

Geographically, North America holds a dominant position due to strong research infrastructure, extensive biotechnology activity, advanced healthcare systems, and high oncology research spending. Europe maintains a significant market presence supported by collaborative clinical research networks and regulatory harmonization initiatives. Asia-Pacific is expected to witness the fastest growth due to large patient populations, cost advantages, improving regulatory environments, and expanding clinical research capabilities in countries such as China, India, Japan, and South Korea.

Competitive and Strategic Outlook

The competitive landscape is characterized by the presence of pharmaceutical companies, biotechnology firms, contract research organizations, academic research centers, and specialized oncology service providers. Competition is centered on trial execution capabilities, patient recruitment efficiency, biomarker expertise, data analytics capabilities, and global operational reach.

Organizations are increasingly investing in artificial intelligence, genomic technologies, decentralized trial platforms, and advanced data management systems to improve study performance and accelerate regulatory success. Strategic partnerships between sponsors and CROs continue to increase as companies seek specialized expertise in precision oncology and complex clinical trial execution.

Mergers, acquisitions, technology partnerships, and service expansion initiatives are expected to remain common as market participants strengthen their competitive positions and broaden their oncology research capabilities. The growing importance of personalized medicine and targeted therapies will continue to drive demand for specialized oncology clinical trial services.

Conclusion

The global oncology clinical trials market is positioned for sustained growth through 2031, supported by rising cancer incidence, expanding precision medicine applications, increasing oncology research investments, and continuous innovation in clinical trial methodologies. Advances in genomics, artificial intelligence, biomarker-driven research, and decentralized clinical trial technologies are transforming how oncology studies are designed and executed. While challenges related to costs, recruitment complexity, and regulatory requirements remain, ongoing technological progress and strong industry investment are expected to create substantial opportunities across the oncology clinical research ecosystem.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Overview
• 1.2 Scope of the Report
• 1.3 Definition of Oncology Clinical Trials
• 1.4 Key Findings
• 1.5 Clinical Trial Trends in Oncology
• 1.6 Innovation and Development Outlook
• 1.7 Key Strategic Insights
• 1.8 Analyst Recommendations

2. Oncology Clinical Development Overview

• 2.1 Introduction to Oncology Clinical Research
• 2.2 Evolution of Oncology Clinical Trials
• 2.3 Precision Oncology and Biomarker Integration
• 2.4 Role of Genomic Profiling in Trial Design
• 2.5 Immuno-Oncology Clinical Development Trends
• 2.6 Cell & Gene Therapy Clinical Expansion
• 2.7 Emerging Oncology Technology Platforms
• 2.8 Oncology Trial Ecosystem Analysis

3. Oncology Clinical Trials Landscape Report Dynamics

• 3.1 Market Drivers
  • 3.1.1 Expansion of Precision Oncology Trials
  • 3.1.2 Growth of Immuno-Oncology Combination Studies
  • 3.1.3 Increasing Investment in Cell Therapy Trials
  • 3.1.4 Rising Biomarker-Guided Trial Enrollment
• 3.2 Market Restraints
  • 3.2.1 High Clinical Trial Costs
  • 3.2.2 Patient Recruitment Complexity
  • 3.2.3 Regulatory Delays and Compliance Burden
  • 3.2.4 Biomarker Validation Challenges
• 3.3 Market Opportunities
  • 3.3.1 Expansion of Decentralized Oncology Trials
  • 3.3.2 AI Integration in Trial Optimization
  • 3.3.3 Growth of ADC Clinical Programs
  • 3.3.4 Emerging Market Trial Expansion
• 3.4 Market Challenges
  • 3.4.1 Trial Failure Risk
  • 3.4.2 Data Management Complexity
  • 3.4.3 Competition for Patient Enrollment
  • 3.4.4 Manufacturing Constraints in Cell Therapy Trials
• 3.5 Porter's Five Forces Analysis
• 3.6 PESTLE Analysis
• 3.7 Investment & Funding Landscape
• 3.8 Clinical Trial Benchmarking Analysis

4. Oncology Clinical Trials Landscape

• 4.1 Overview of Global Oncology Clinical Trials
• 4.2 Oncology Trials by Phase
  • 4.2.1 Phase I
  • 4.2.2 Phase II
  • 4.2.3 Phase III
  • 4.2.4 Phase IV
• 4.3 Clinical Trials by Therapy Type
  • 4.3.1 Immuno-Oncology
  • 4.3.2 Targeted Therapy
  • 4.3.3 Cell Therapy
  • 4.3.4 Gene Therapy
  • 4.3.5 Antibody-Drug Conjugates
  • 4.3.6 Radiopharmaceutical Oncology
• 4.4 Clinical Trials by Cancer Type
  • 4.4.1 Lung Cancer
  • 4.4.2 Breast Cancer
  • 4.4.3 Colorectal Cancer
  • 4.4.4 Prostate Cancer
  • 4.4.5 Gastric Cancer
  • 4.4.6 Liver Cancer
  • 4.4.7 Pancreatic Cancer
  • 4.4.8 Ovarian Cancer
  • 4.4.9 Cervical Cancer
  • 4.4.10 Melanoma
  • 4.4.11 Leukemia
  • 4.4.12 Lymphoma
  • 4.4.13 Multiple Myeloma
• 4.5 Biomarker-Driven Clinical Trial Trends
• 4.6 Adaptive and Basket Trial Models
• 4.7 Decentralized Oncology Trial Expansion
• 4.8 Companion Diagnostic Integration
• 4.9 Clinical Trial Collaboration Trends
• 4.10 Key Clinical Trial Case Studies

5. Innovation & Pipeline Trial Analysis

• 5.1 Oncology Pipeline Trial Overview
• 5.2 Immuno-Oncology Trial Expansion
• 5.3 ADC Clinical Development Trends
• 5.4 Cell & Gene Therapy Trial Analysis
• 5.5 KRAS Inhibitor Trial Landscape
• 5.6 Bispecific Antibody Clinical Programs
• 5.7 Combination Therapy Trial Strategies
• 5.8 AI-Enabled Oncology Trial Optimization
• 5.9 Emerging Oncology Modalities
• 5.10 Future Clinical Trial Hotspots

6. Treatment & Commercialization Landscape

• 6.1 Current Oncology Treatment Landscape
• 6.2 Clinical Trial Impact on Commercialization
• 6.3 Companion Diagnostic Commercial Integration
• 6.4 Precision Medicine Market Expansion
• 6.5 Market Access and Reimbursement Implications
• 6.6 Post-Approval Clinical Development Strategies
• 6.7 Lifecycle Management Through Clinical Trials
• 6.8 Competitive Positioning Through Clinical Innovation

7. Oncology Clinical Trials Landscape Report Size & Forecast

• 7.1 Global Oncology Clinical Trials Market Overview
• 7.2 Historical Clinical Trial Activity Analysis
• 7.3 Market Forecast Methodology
• 7.4 Oncology Trial Volume Forecast (2026-2035)
• 7.5 Investment Forecast
• 7.6 Forecast by Therapy Type
• 7.7 Forecast by Trial Phase
• 7.8 Forecast by Cancer Type
• 7.9 Forecast by Region
• 7.10 Future Innovation Outlook

8. Oncology Clinical Trials Landscape Report Segmentation

• 8.1 By Trial Phase
  • 8.1.1 Phase I
  • 8.1.2 Phase II
  • 8.1.3 Phase III
  • 8.1.4 Phase IV
• 8.2 By Therapy Type
  • 8.2.1 Immuno-Oncology
  • 8.2.2 Targeted Therapy
  • 8.2.3 Cell Therapy
  • 8.2.4 Gene Therapy
  • 8.2.5 Antibody-Drug Conjugates
  • 8.2.6 Radiopharmaceutical Oncology
• 8.3 By Cancer Type
  • 8.3.1 Lung Cancer
  • 8.3.2 Breast Cancer
  • 8.3.3 Colorectal Cancer
  • 8.3.4 Prostate Cancer
  • 8.3.5 Gastric Cancer
  • 8.3.6 Liver Cancer
  • 8.3.7 Pancreatic Cancer
  • 8.3.8 Ovarian Cancer
  • 8.3.9 Cervical Cancer
  • 8.3.10 Melanoma
  • 8.3.11 Leukemia
  • 8.3.12 Lymphoma
  • 8.3.13 Multiple Myeloma
• 8.4 By End User
  • 8.4.1 Pharmaceutical Companies
  • 8.4.2 Biotechnology Companies
  • 8.4.3 Academic & Research Institutes
  • 8.4.4 Contract Research Organizations

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Clinical Trial Activity Overview
  • 9.1.2 Investment Trends
  • 9.1.3 Regulatory Environment
  • 9.1.4 Competitive Clinical Research Landscape
• 9.2 Europe
  • 9.2.1 Clinical Trial Activity Overview
  • 9.2.2 Investment Trends
  • 9.2.3 Regulatory Environment
  • 9.2.4 Competitive Clinical Research Landscape
• 9.3 Asia-Pacific
  • 9.3.1 Clinical Trial Activity Overview
  • 9.3.2 Investment Trends
  • 9.3.3 Regulatory Environment
  • 9.3.4 Competitive Clinical Research Landscape
• 9.4 Latin America
  • 9.4.1 Clinical Trial Activity Overview
  • 9.4.2 Investment Trends
  • 9.4.3 Regulatory Environment
  • 9.4.4 Competitive Clinical Research Landscape
• 9.5 Middle East & Africa
  • 9.5.1 Clinical Trial Activity Overview
  • 9.5.2 Investment Trends
  • 9.5.3 Regulatory Environment
  • 9.5.4 Competitive Clinical Research Landscape

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Oncology Trial Volume Analysis
  • 10.1.2 FDA Clinical Trial Framework
  • 10.1.3 Precision Oncology Adoption
  • 10.1.4 Key Sponsors and Research Centers
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 FDA Oncology Clinical Trial Framework
• 11.2 EMA Clinical Trial Regulations
• 11.3 PMDA Oncology Trial Guidelines
• 11.4 CDSCO Clinical Trial Requirements
• 11.5 NMPA Oncology Approval Framework
• 11.6 Biomarker Validation Regulations
• 11.7 Companion Diagnostic Regulations
• 11.8 Ethical and Patient Recruitment Policies
• 11.9 Decentralized Trial Regulatory Trends
• 11.10 Future Regulatory Outlook

12. Competitive Landscape

• 12.1 Leading Oncology Trial Sponsors
• 12.2 Competitive Benchmarking
• 12.3 Clinical Trial Pipeline Comparison
• 12.4 Strategic Collaboration Analysis
• 12.5 CRO and Research Partnership Trends
• 12.6 Emerging Oncology Innovators
• 12.7 Investment Benchmarking
• 12.8 SWOT Analysis of Major Players

13. Company Profiles

• 13.1 Roche
  • 13.1.1 Oncology Clinical Trial Strategy
  • 13.1.2 Immuno-Oncology Programs
  • 13.1.3 Biomarker Integration Approach
  • 13.1.4 ADC and Combination Therapy Trials
• 13.2 Merck & Co.
  • 13.2.1 Keytruda Clinical Expansion
  • 13.2.2 Combination Therapy Programs
  • 13.2.3 Precision Oncology Trial Strategy
• 13.3 Bristol Myers Squibb
  • 13.3.1 Immuno-Oncology Trial Portfolio
  • 13.3.2 Cell Therapy Clinical Programs
  • 13.3.3 Hematologic Oncology Studies
• 13.4 AstraZeneca
  • 13.4.1 Targeted Therapy Trial Expansion
  • 13.4.2 ADC Clinical Programs
  • 13.4.3 Lung Cancer Trial Leadership
• 13.5 Pfizer
  • 13.5.1 Precision Oncology Clinical Strategy
  • 13.5.2 Targeted Therapy Development
  • 13.5.3 Global Trial Expansion
• 13.6 Novartis
  • 13.6.1 Cell & Gene Therapy Clinical Programs
  • 13.6.2 Radioligand Oncology Trials
  • 13.6.3 Hematologic Oncology Development
• 13.7 Johnson & Johnson Innovative Medicine
  • 13.7.1 Hematology Oncology Trials
  • 13.7.2 Combination Therapy Programs
  • 13.7.3 Commercialization-Oriented Trial Strategy
• 13.8 Gilead Sciences
  • 13.8.1 Cell Therapy Clinical Development
  • 13.8.2 ADC Trial Programs
  • 13.8.3 Manufacturing and Trial Expansion
• 13.9 Eli Lilly and Company
  • 13.9.1 Precision Oncology Trial Strategy
  • 13.9.2 KRAS Inhibitor Development
  • 13.9.3 Biomarker-Focused Clinical Programs
• 13.10 Amgen
  • 13.10.1 Bispecific Antibody Clinical Programs
  • 13.10.2 Oncology Trial Expansion
  • 13.10.3 Clinical Development Activities

14. Future Outlook

• 14.1 Future of Oncology Clinical Trials
• 14.2 Expansion of Precision Oncology Studies
• 14.3 AI-Enabled Clinical Development
• 14.4 Future of Decentralized Oncology Trials
• 14.5 Next-Generation Immuno-Oncology Development
• 14.6 Future Investment Landscape
• 14.7 Analyst Recommendations

15. Methodology

• 15.1 Research Methodology
• 15.2 Data Collection Sources
• 15.3 Secondary Research
• 15.4 Primary Research
• 15.5 Clinical Trial Validation Methodology
• 15.6 Forecasting Techniques
• 15.7 Data Triangulation
• 15.8 Assumptions & Limitations
• 15.9 Abbreviations & Definitions